Kiniksa Pharmaceuticals International, plc KNSA

75.08 (0.26) (0.35%) as of 25 Sep
Market cap
$5.9B
P/E
70.2×
Growth Flags show if company had growth for consecutive years

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Net Income

+8 more TTM periods

35.92 59.01 73.06 80.66
Depreciation & Amortization 1.49 1.55 1.68 1.79
Non Cash Items (Other) 46.00 52.64 57.62 61.47
Accounts Receivable Change (26.85) 26.13 16.84 8.42
Change in inventories (12.72) (28.53) (51.07) (22.75)
Accounts Payable Change (2.02) 0.14 22.35 3.42
Change in other assets and liabilities 61.04 27.05 45.40 51.96
Operating Cash Flow 102.86 137.99 165.86 184.97
Capital expenditures (1.13) (1.57) (1.63) (2.13)
Short Term Investments Change (Net) (51.76) (187.42) (167.74) (236.94)
Investing cash flow (52.89) (188.99) (169.37) (239.06)
Equity Repurchase (Common, Net) 34.90 40.75 43.96 48.80
Other financial activities (7.39) (7.73) (7.63) (11.05)
Financing cash flow 27.51 33.02 36.33 37.74
Change in Cash 77.48 (17.98) 32.82 (16.36)
Beginning Cash 183.58 183.58 165.60 165.60
Ending Cash 261.06 165.60 198.42 149.24
Stock Based Compensation 35.07 37.00 39.31 42.07
Dividends Paid (Common) 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total) 19.45 24.79 33.51 41.04
Investments Change (Net) (51.76) (187.42) (167.74) (236.94)
Issuance/Purchase of Shares 34.90 40.75 43.96 48.80

Fold the line items

In millions of $ except per-share values · columns are period end dates